Oppenheimer raised the firm’s price target on Ventyx Biosciences (VTYX) to $14 from $9 and keeps an Outperform rating on the shares. The firm notes Ventyx announced Phase 2 data for CNS penetrant VTX3232 that changed up the story significantly. The data highlighted rapid reductions in hsCRP and other inflammatory biomarkers in this population of obese patients with cardiovascular risk factors. While these results closed the chapter on NLRP3 inhibitors in obesity, they threw open the door to addressing a validated biomarker for cardiovascular risk in hsCRP, Oppenheimer argues.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTYX:
- Promising Phase II Trial Results of VTX3232 Bolster Buy Rating for Ventyx Biosciences
- Midday Fly By: Tesla reports mixed Q3, Trump in talks for quantum stakes
- Video: Lackluster Tesla and IBM quarters weighing on sentiment
- Why Is Ventyx Biosciences Stock (VTYX) Up 105% Today?
- Ventyx ‘unequivocally impressive data’ should spur Sanofi, says Clear Street